Additionally, in the era of molecular-integrated risk profiles for endometrial cancer [45,46], the role of targeted therapies, based on molecular characteristics like HER2 overexpression or mismatch repair deficiency, should be considered alongside standard chemotherapy. This evidence concerns the gene ERBB2 and hyperinsulinemic hypoglycemia, familial, 4.